Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Agalsidase beta		NHSE commissioned
Ajmaline IV
Albumin human solution
Albumin solution
Alemtuzumab concentrate for infusion	TA312 - Alemtuzumab for treating relapsing-remitting multiple sclerosis	Hospital use only
Alfacalcidol injection
Alfentanil injection
Alfentanil intensive care®		High strength - Pallative care team recommendation during end of life care only
Alglucosidase alfa injection		NHSE commissioned.
Alirocumab (Praluent®)	TA393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia	To be used in line with NICE TA

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.